FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2525417966> ?p ?o ?g. }

• W2525417966 endingPage "502" @default.
• W2525417966 startingPage "496" @default.
• W2525417966 abstract "Respiratory syncytial virus (RSV) remains a significant cause of morbidity and mortality in infants and young children, immunocompromised patients and the elderly. Despite the high disease burden, an effective and safe vaccine is lacking, although several candidates are currently in development. Current treatment for RSV infection remains largely supportive and RSV-specific options for prophylaxis are limited to palivizumab. In the past few years, novel therapeutic options including nanobodies, polyclonal and monoclonal antibodies have emerged and there are several products in preclinical and Phase-I, -II or -III clinical trials. The major target for antiviral drug development is the surface fusion (F) glycoprotein, which is crucial for the infectivity and pathogenesis of the virus. Solving the structures of the two conformations of the RSV F protein, the prefusion and postfusion forms, has revolutionized RSV research. It is now known that prefusion F is highly superior in inducing neutralizing antibodies. In this section we will review the stages of development and availability of different antibodies directed against RSV for the prevention and also for treatment of acute RSV infections. Some of these newer anti-RSV agents have shown enhanced potency, are being explored through alternative routes of administration, have improved pharmacokinetic profiles with an extended half-life, and may reduce design and manufacturing costs. Management strategies will require targeting not only high-risk populations (including adults or immunocompromised patients), but also previously healthy children who, in fact, represent the majority of children hospitalized with RSV infection. Following treated patients longitudinally is essential for determining the impact of these strategies on the acute disease as well as their possible long-term benefits on lung morbidity." @default.
• W2525417966 created "2016-10-07" @default.
• W2525417966 creator A5009464778 @default.
• W2525417966 creator A5018518714 @default.
• W2525417966 creator A5018978935 @default.
• W2525417966 creator A5049592946 @default.
• W2525417966 creator A5063403238 @default.
• W2525417966 date "2017-01-01" @default.
• W2525417966 modified "2023-10-13" @default.
• W2525417966 title "Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection" @default.
• W2525417966 cites W1527926071 @default.
• W2525417966 cites W1587614700 @default.
• W2525417966 cites W1857608076 @default.
• W2525417966 cites W1921480186 @default.
• W2525417966 cites W1962254654 @default.
• W2525417966 cites W1965140613 @default.
• W2525417966 cites W1972873370 @default.
• W2525417966 cites W1984286626 @default.
• W2525417966 cites W1986189079 @default.
• W2525417966 cites W2003652041 @default.
• W2525417966 cites W2004663239 @default.
• W2525417966 cites W2019706667 @default.
• W2525417966 cites W2020573529 @default.
• W2525417966 cites W2021223055 @default.
• W2525417966 cites W2029503764 @default.
• W2525417966 cites W2035573793 @default.
• W2525417966 cites W2042975473 @default.
• W2525417966 cites W2043056303 @default.
• W2525417966 cites W2043372033 @default.
• W2525417966 cites W2052633053 @default.
• W2525417966 cites W2053347879 @default.
• W2525417966 cites W2055180355 @default.
• W2525417966 cites W2066243349 @default.
• W2525417966 cites W2066370188 @default.
• W2525417966 cites W2077290707 @default.
• W2525417966 cites W2081189029 @default.
• W2525417966 cites W2081356514 @default.
• W2525417966 cites W2086373045 @default.
• W2525417966 cites W2091243638 @default.
• W2525417966 cites W2093529351 @default.
• W2525417966 cites W2094048920 @default.
• W2525417966 cites W2096309099 @default.
• W2525417966 cites W2098161574 @default.
• W2525417966 cites W2102553812 @default.
• W2525417966 cites W2105754568 @default.
• W2525417966 cites W2110547872 @default.
• W2525417966 cites W2114446982 @default.
• W2525417966 cites W2117503809 @default.
• W2525417966 cites W2120949068 @default.
• W2525417966 cites W2125065061 @default.
• W2525417966 cites W2128049245 @default.
• W2525417966 cites W2134224958 @default.
• W2525417966 cites W2142073032 @default.
• W2525417966 cites W2143643431 @default.
• W2525417966 cites W2145783587 @default.
• W2525417966 cites W2146453977 @default.
• W2525417966 cites W2147480427 @default.
• W2525417966 cites W2148090354 @default.
• W2525417966 cites W2151727763 @default.
• W2525417966 cites W2153221884 @default.
• W2525417966 cites W2155130452 @default.
• W2525417966 cites W2156857299 @default.
• W2525417966 cites W2159725619 @default.
• W2525417966 cites W2168919455 @default.
• W2525417966 cites W2169665123 @default.
• W2525417966 cites W2190300929 @default.
• W2525417966 cites W2198743132 @default.
• W2525417966 cites W2321281439 @default.
• W2525417966 cites W2328116798 @default.
• W2525417966 cites W2330176961 @default.
• W2525417966 cites W2338102897 @default.
• W2525417966 cites W2517356996 @default.
• W2525417966 cites W4212838542 @default.
• W2525417966 cites W4245170709 @default.
• W2525417966 cites W4292315834 @default.
• W2525417966 doi "https://doi.org/10.1016/j.vaccine.2016.09.026" @default.
• W2525417966 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5183505" @default.
• W2525417966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27692523" @default.
• W2525417966 hasPublicationYear "2017" @default.
• W2525417966 type Work @default.
• W2525417966 sameAs 2525417966 @default.
• W2525417966 citedByCount "39" @default.
• W2525417966 countsByYear W25254179662017 @default.
• W2525417966 countsByYear W25254179662018 @default.
• W2525417966 countsByYear W25254179662019 @default.
• W2525417966 countsByYear W25254179662020 @default.
• W2525417966 countsByYear W25254179662021 @default.
• W2525417966 countsByYear W25254179662022 @default.
• W2525417966 countsByYear W25254179662023 @default.
• W2525417966 crossrefType "journal-article" @default.
• W2525417966 hasAuthorship W2525417966A5009464778 @default.
• W2525417966 hasAuthorship W2525417966A5018518714 @default.
• W2525417966 hasAuthorship W2525417966A5018978935 @default.
• W2525417966 hasAuthorship W2525417966A5049592946 @default.
• W2525417966 hasAuthorship W2525417966A5063403238 @default.
• W2525417966 hasBestOaLocation W25254179662 @default.
• W2525417966 hasConcept C126322002 @default.
• W2525417966 hasConcept C159047783 @default.

• next